PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Regulation FD Disclosure

Item7.01.

Pulmatrix, Inc. (the Company) intends, from time to time, to
present and/or distribute to the investment community and utilize
at various industry and other conferences a slide presentation,
which is attached hereto as Exhibit 99.1. The Company undertakes
no obligation to update, supplement or amend the materials
attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the
information in this Item7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed filed for the
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the
Securities Act of 1933, as amended, except as shall be expressly
set forth by reference in such a filing. Furthermore, the
furnishing of information under Item7.01 of this Current Report
on Form 8-K is not intended to constitute a determination by the
Company that the information contained herein, including the
exhibits hereto, is material or that the dissemination of such
information is required by Regulation FD.

(d) Exhibits.

About PULMATRIX, INC. (NASDAQ:PULM)

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

PULMATRIX, INC. (NASDAQ:PULM) Recent Trading Information

PULMATRIX, INC. (NASDAQ:PULM) closed its last trading session down -0.02 at 3.48 with 372,751 shares trading hands.